Equivalence Study of Dorzolamide 2% Eye Drops Solution

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to prospectively prove the equivalence of the test product and the reference solution in lowering intraocular pressure in patients with open angle glaucoma and ocular hypertension. For this purpose the patients are randomized into two sequences of study drug administration in a crossover study with an adequate wash-out period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)

NCT00108017

Glaucoma Ocular Hypertension

COMPLETED PHASE3

24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination

NCT00972257

Glaucoma

COMPLETED PHASE4

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

NCT01173471

Raised Intraocular Pressure

COMPLETED PHASE2

A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension

NCT00471380

Glaucoma Ocular Hypertension

COMPLETED PHASE4

Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT00822081

Open-Angle Glaucoma Ocular Hypertension

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open Angle Glaucoma Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dorzolamide

Group Type EXPERIMENTAL

Dorzolamide 2 % eye drops solution

Intervention Type DRUG

1 drop into eye(s) three times a day for the duration of each treatment phase

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dorzolamide 2 % eye drops solution

1 drop into eye(s) three times a day for the duration of each treatment phase

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients of any race aged 18 years or older
* A clinical diagnosis of open angle glaucoma, pseudoexfoliation or pigment dispersion glaucoma, or ocular hypertension in one or both eyes
* IOP controllable on one drug treatment in the study eye in way that assures clinical stability of vision and the optic nerve throughout the study
* Baseline IOP between 18 and 32 mmHg in the study eye (in eyes not included in the study IOP must have been controllable on no pharmacologic treatment or on the study medicine only)
* Best corrected visual acuity of 20/200 or better in the study eye(s)
* Ability of subject to understand character and individual consequences of clinical trial
* Signed and dated informed consent of the subject must be available before start of any specific trial procedures
* Women with childbearing potential have to practicing a medically accepted contraception during trial and a negative pregnancy test (serum or urine) should be existent before trial. Reliable contraception are systemic contraceptives (oral, implant, injection) and diaphragm or condoms with spermicidal. Women that are sterile by surgery or for more than two years postmenopausal can be participate in the trial.

Exclusion Criteria

* Chronic or recurrent inflammatory eye disease
* Ocular trauma within the past six months
* Current ocular infection, i.e. conjunctivitis or keratitis
* Any abnormality preventing reliable applanation tonometry
* Intraocular surgery or laser treatment within the past three months
* Inability to discontinue contact lens wear during the study
* Use of any systemic medication that would affect IOP with less than a

1-month stable dosing regimen before the screening visit
* Pregnancy and lactation
* History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
* Participation in other clinical trials during the present clinical trial or within the last four weeks
* Medical or psychological condition that would not permit completion of the trial or signing of informed consent
* Subject is allergic to sulfonamides
* Severe renal dysfunction or hyperchloraemic acidosis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No